Kidney complications following COVID-19 vaccination; a review of the literature

Hassanzadeh, Shakiba; Djamali, Arjang; Mostafavi, Leila; Pezeshgi, Aiyoub

doi:10.34172/npj.2022.01

Cited by 7 publications

(10 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the AAV manifestations responded well to ribonuclease treatment in the vaccinated patients [ 33 , 34 ]. Unfortunately, the pathogenesis of ANCA-GN followed by the COVID-19 vaccine remains obscure [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

“…Then the ANCA ignites the inflammation cascade pathway by producing inflammatory cytokines (e.g., type 1 interferon, interleukin-6), activating Toll-like receptor (TLR), priming and activating neutrophils, causing neutrophils extracellular traps (NETs) formation, a mesh-like structure comprising DNA, histone, and neutrophil granules (e.g., MPO, PR3). Thus, MPO and PR3 on the NETs might further fuel the inflammatory fire and viciously start the ANCA production cascade [ 9 , 35 , 36 , 37 , 39 ]. mRNA vaccination in mice, monkeys, and humans activates TLR3, TLR4, and TLR7, causing robust cytotoxic T-lymphocyte activation [ 40 , 41 , 42 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review

et al. 2023

View full text Add to dashboard Cite

Vaccines against SARS-CoV-2 (COVID-19) proved beneficial for COVID-19 disease attenuation and preventing virus spreading. Cumulative reports of the rarity of antineutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis (AAV) raise concerns about its relationship with COVID-19 vaccination. Several case reports described ANCA-associated pauci-immune glomerulonephritis (ANCA-GN) following COVID-19 vaccination with some uniqueness. We systematically reviewed COVID-19 vaccine-induced ANCA-GN from PubMed, SCOPUS, and Cochrane library databases until 1 January 2023 according to PRISMA guidelines and presented our three cases. Twenty-six cases from 25 articles, including our 3 cases, were analyzed. Most cases were diagnosed following the second dose of the COVID-19 vaccine (59%) with a median (IQR) interval onset of 14 (16) days. The highest prevalence was related to the mRNA-type vaccine. Anti-myeloperoxidase (MPO) ANCA was far more common than the other ANCAs, with various positive autoantibodies. Fourteen cases (out of 29 cases, 48%) had extra-kidney AAV manifestation. Although severe kidney injury was observed in 10/29 (34%), remission was achieved in 89% (25/28) with no death. The mechanisms of the vaccine-inducing ANCA-GN were postulated here. Since ANCA-GN after the COVID-19 vaccine was rare, the benefit of the COVID-19 vaccine could outweigh the risk of ANCA-GN side effects in the pandemic era.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…However, the types and levels of systemic and organ side effects of these vaccines are not fully known. 2 …”

Section: Introductionmentioning

confidence: 99%

Effects of Repeated Doses of the Vero Cell Vaccine (SARS-Cov-2 Inactivated Vaccine) on Renal Functions in Balb/C Albino Mice

Köse,

Yılmaz,

Kıratlı

et al. 2024

JIR

View full text Add to dashboard Cite

Objective Many of the vaccines developed for COVID-19 have been approved for clinical emergency use before their safety and preclinical studies have been completed. The main aim of this study was to investigate the effects of an inactivated SARS-CoV-2 virus vaccine (Vero cells) on renal function in Balb/C Albino mice. Methods 21 healthy, 6–8 week old BALB/c male mice were divided into three equal groups, and 0.10 mL of intramuscular saline equal to the vaccine dose volume was administered to the first group. To the second group, a single dose of 0.10 mL 120 U of Vero cell inactive SARS COV-2 vaccine was administered intramuscularly. Group 3 received two consecutive doses of 0.10 mL 120 U intramuscular Vero cell inactive SARS COV-2 vaccine, 14 days apart. After administration, the clinical status, fecal and urine status, nutritional status and kidney histopathology of the mice were evaluated. Results It was determined that no acute toxic symptoms were observed in the mice administered the vaccine, they were in good condition, and there was no significant stimulatory reaction related to the vaccine in the tissues of the injected local area. There was no difference in feed consumption, water consumption, and body weight gains between the control group, the groups that received a single dose of vaccine, and the groups that received two doses of vaccine (p>0.05). No difference was found between the groups when urine and feces amounts were compared (p>0.05). No difference was found between the groups when urinary urea, creatinine, and serum BUN, creatinine levels were compared (p>0.05). No difference was found in the histopathological evaluation of the kidneys between the groups (p>0.05). Conclusion In conclusion, single or repeated injections of the SARS-CoV-2 vaccine (Vero cells) into mice were found to have no adverse effects on the animals’ overall clinical health, performance abilities and kidneys.

show abstract

“…Most cases involved glomerular disease representing nephrotic syndrome. Recently, several reports have focused on glomerular diseases, such as minimal change disease and immunoglobulin (Ig)A nephropathy, after COVID-19 vaccination [ 3 4 5 ]. Acute interstitial nephritis (AIN) is usually a concomitant finding with other glomerular diseases, and there have been few reports of AIN occurring in isolation after COVID-19 vaccination.…”

Section: Introductionmentioning

confidence: 99%

Acute interstitial nephritis with acute kidney injury after COVID-19 vaccination: a case report

Lim,

Paek,

Shin

et al. 2024

Clin Exp Vaccine Res

View full text Add to dashboard Cite

In the context of the massive spread of coronavirus disease 2019 (COVID-19), the development of a COVID-19 vaccine is urgently needed. The Pfizer-BioNTech COVID-19 vaccine has been widely applied across global populations. Herein, we report a case of acute interstitial nephritis with acute kidney injury in a young healthy subject after administration of the COVID-19 vaccine. A 20-year-old man was admitted with abdominal discomfort and nausea. He had received the Pfizer-BioNTech COVID-19 vaccine 6 days before. At 9 days after vaccination, his kidney function was decreased, with serum creatinine levels of 1.8 mg/dL. Even with supportive care with hydration, his kidney function worsened, and he underwent a kidney biopsy. The pathology findings revealed diffuse interstitial infiltration of inflammatory cells, predominantly comprising lymphocytes, with preservation of the glomerulus. No abnormal findings were noted by immunofluorescence or electron microscopy. Based on a diagnosis of drug-related acute interstitial nephritis, we treated the patient with high-dose prednisolone. After administration of prednisolone, kidney function slowly improved. A close linkage between COVID-19 vaccination and acute interstitial nephritis should be considered in the clinic, despite the low incidence.

show abstract

Kidney complications following COVID-19 vaccination; a review of the literature

Cited by 7 publications

References 78 publications

ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review

ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review

Effects of Repeated Doses of the Vero Cell Vaccine (SARS-Cov-2 Inactivated Vaccine) on Renal Functions in Balb/C Albino Mice

Acute interstitial nephritis with acute kidney injury after COVID-19 vaccination: a case report

Contact Info

Product

Resources

About